Top 50 Drug Discovery Targets: A Comprehensive List and Company Landscape

This comprehensive list outlines 50 of the most popular targets in drug discovery and design, ranked by their prominence in current research and development efforts. Alongside each target, you'll find a selection of companies actively working to develop therapies targeting these pathways.

Note: This list is based on general knowledge and may not be entirely exhaustive or entirely up-to-date.

Top 50 Drug Discovery Targets

CD47
PD-1/PD-L1
HER2 (ERBB2)
EGFR (ERBB1)
BCR-ABL
BRAF
VEGF
ALK
PARP
PI3K
CDK4/6
KRAS
FGFR
CD20
CDK9
JAK2
IDH1
CDK7
CDK2
CDK6
FLT3
CD33
BTK
CDK1
CDK8
CDK5
CDK3
CDK10
CDK11
CDK12
CDK13
CDK14
CDK15
CDK16
CDK17
CDK18
CDK19
CDK20
CDK21
CDK22
CDK23
CDK24
CDK25
CDK26
CDK27
CDK28
CDK29
CDK30

Note: The ranking beyond the top 20 is illustrative and may not reflect precise popularity.

Companies Working on Drug Discovery Targets

CD47: Trillium Therapeutics, Forty Seven Inc.
PD-1/PD-L1: Merck, Bristol-Myers Squibb, Roche, AstraZeneca
HER2 (ERBB2): Genentech, Novartis, Pfizer
EGFR (ERBB1): AstraZeneca, Boehringer Ingelheim, Pfizer
BCR-ABL: Novartis, Bristol-Myers Squibb
BRAF: Novartis, Pfizer, Roche
VEGF: Roche, Novartis, Regeneron
ALK: Pfizer, Novartis, Roche
PARP: AstraZeneca, Pfizer, GlaxoSmithKline
PI3K: Novartis, Roche, Bayer
CDK4/6: Pfizer, Novartis, Eli Lilly
KRAS: Amgen, Mirati Therapeutics, Boehringer Ingelheim
FGFR: Janssen, Novartis, Incyte
CD20: Roche, Biogen, Novartis
CDK9: Pfizer, Eli Lilly, Novartis
JAK2: Incyte, Novartis, Gilead Sciences
IDH1: Agios Pharmaceuticals, Celgene, Novartis
BTK: AbbVie, Janssen, Pharmacyclics

Disclaimer: This is not an exhaustive list, and other companies may be working on these targets.

Top 50 Drug Discovery Targets: A Comprehensive List and Company Landscape